Source: Virtual Congress 2021 – Accurate diagnosis and prediction of malignant pleural disease



Rating:

Share or cite this content

Citations should be made in the following way:
J. Rodriguez Torres (Granada, Spain), L. López-López (Granada, Spain), M. Granados-Santiago (Granada, Spain), E. Prados-Roman (Granada, Spain), A. Heredia-Ciuró (Granada, Spain), M. Valenza (Granada, Spain). Impact of sarcopenia in long-term symptoms in patients with malignant pleural effusion.. 3100

Member's Comments

No comment yet.

Related content which might interest you: Predictors of survival in patients with recurrent malignant pleural effusion Source: Annual Congress 2008 - Diagnostic and therapeutic approaches in pleural diseases Year: 2008 Influence of psychological distress on symptom burden of patients admitted by malignant pleural effusion Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Impact of indwelling pleural catheter on quality of life in management of malignant pleural effusion in patients with advanced malignancies Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Parapneumonic pleural effusion as a cause of hypoalbumunemia in pediatric patients Source: Eur Respir J 2006; 28: Suppl. 50, 309s Year: 2006 Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion? Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017 The pathophysiology of breathlessness and other symptoms associated with pleural effusions Source: Eur Respir Monogr 2020; 87: 13-28 Year: 2020 Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007 Histology, performance status and lymphopenia are factors of survival in patients undergoing thoracoscopy for malignant pleural effusion Source: Annual Congress 2009 - Trends in bronchoscopy Year: 2009 Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004 Peculiarities of accompanying clinically mild pleural effusion to patients of different age Source: Eur Respir J 2002; 20: Suppl. 38, 345s Year: 2002 Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019 The importance of intrapleurally γ-interferon in ambulatory management of malignant pleural effusion in elderly patients with end-stage NSCCL Source: Eur Respir J 2005; 26: Suppl. 49, 495s Year: 2005 Evaluation of patients with pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 247s Year: 2004 Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Effecs of systemic inflammation markers for determining success of talc pleurodeisis on patients with malignant pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Management of recurrent malignant pleural effusions Source: ERS Skills Course 2016 Year: 2016 Management of recurrent malignant pleural effusions Source: ERS Skills Course 2017 - Thoracoscopy and Pleural Techniques Year: 2017 Management of recurrent malignant pleural effusions Source: ERS Skills Course 2016 - Thoracoscopy and pleural techniques Year: 2016 Management of recurrent malignant pleural effusions Source: ERS Skills Course 2018 - Thoracoscopy and pleural techniques Year: 2018 Management of recurrent malignant pleural effusions Source: ERS Course 2019 - Thoracoscopy and Pleural Techniques Year: 2019